What's in Suzhou Alphamab Co., Ltd.'s pipeline?

Suzhou Alphamab Co., Ltd. has 7 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 4 in Phase 2, 2 in Phase 1.

Which companies overlap with Suzhou Alphamab Co., Ltd.'s portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Elixiron Immunotherapeutics (Hong Kong) Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., EMD Serono.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/suzhou-alphamab-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Suzhou Alphamab Co., Ltd. — Portfolio Competitive Intelligence Brief

Suzhou Alphamab Co., Ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 4 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
KN057	KN057	phase 3	OX40 agonist monoclonal antibody	OX40	Oncology

Therapeutic area mix

Oncology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 2 shared drug classes
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 shared drug class
Elixiron Immunotherapeutics (Hong Kong) Ltd. · 1 shared drug class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
EMD Serono · 1 shared drug class
EMS · 1 shared drug class
Cellvax Therapeutics Inc · 1 shared drug class
AstraZeneca · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Suzhou Alphamab Co., Ltd.:

Cite this brief

Drug Landscape (2026). Suzhou Alphamab Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/suzhou-alphamab-co-ltd. Accessed 2026-05-16.